| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis M Shankar-Hari, CL Vale, PJ Godolphin, D Fisher, JPT Higgins, F Spiga, ... Jama 326 (6), 1, 2021 | 507 | 2021 |
| Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma J Zhou, TR Patel, RW Sirianni, G Strohbehn, MQ Zheng, N Duong, ... Proceedings of the National Academy of sciences 110 (29), 11751-11756, 2013 | 318 | 2013 |
| ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells JM Drake, G Strohbehn, TB Bair, JG Moreland, MD Henry Molecular biology of the cell 20 (8), 2207-2217, 2009 | 224 | 2009 |
| WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for … M Shankar-Hari, CL Vale, PJ Godolphin, D Fisher, JPT Higgins, F Spiga, ... jama 326 (6), 499-518, 2021 | 162* | 2021 |
| Novel delivery strategies for glioblastoma J Zhou, KB Atsina, BT Himes, GW Strohbehn, WM Saltzman The Cancer Journal 18 (1), 89-99, 2012 | 148 | 2012 |
| A transcriptomic signature of the hypothalamic response to fasting and BDNF deficiency in Prader-Willi syndrome EG Bochukova, K Lawler, S Croizier, JM Keogh, N Patel, G Strohbehn, ... Cell reports 22 (13), 3401-3408, 2018 | 123 | 2018 |
| COVIDOSE: a phase II clinical trial of low‐dose tocilizumab in the treatment of noncritical COVID‐19 pneumonia GW Strohbehn, BL Heiss, SJ Rouhani, JA Trujillo, J Yu, AJ Kacew, ... Clinical Pharmacology & Therapeutics 109 (3), 688-696, 2021 | 85* | 2021 |
| Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance G Strohbehn, D Coman, L Han, RRT Ragheb, TM Fahmy, AJ Huttner, ... Journal of neuro-oncology 121 (3), 441-449, 2015 | 64 | 2015 |
| Artificial intelligence can cut costs while maintaining accuracy in colorectal cancer genotyping AJ Kacew, GW Strohbehn, L Saulsberry, N Laiteerapong, NA Cipriani, ... Frontiers in Oncology 11, 630953, 2021 | 61 | 2021 |
| Interventional pharmacoeconomics: a novel mechanism for unlocking value AV Serritella, GW Strohbehn, DA Goldstein, AS Lichter, MJ Ratain Clinical Pharmacology & Therapeutics 108 (3), 487-493, 2020 | 58 | 2020 |
| Real world outcomes versus clinical trial results of durvalumab maintenance in veterans with stage III non-small cell lung cancer K Sankar, AK Bryant, GW Strohbehn, L Zhao, D Elliott, D Moghanaki, ... Cancers 14 (3), 614, 2022 | 50 | 2022 |
| Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer AK Bryant, K Sankar, GW Strohbehn, L Zhao, D Elliott, A Qin, S Yentz, ... Lung Cancer 163, 35-41, 2022 | 46 | 2022 |
| Teleoncology for veterans: high patient satisfaction coupled with positive financial and environmental impacts CY Jiang, GW Strohbehn, RM Dedinsky, SM Raupp, BM Pannecouk, ... JCO oncology practice 17 (9), e1362-e1374, 2021 | 46 | 2021 |
| Essential role for hypothalamic calcitonin receptor‒expressing neurons in the control of food intake by leptin W Pan, JM Adams, MB Allison, C Patterson, JN Flak, J Jones, ... Endocrinology 159 (4), 1860-1872, 2018 | 41 | 2018 |
| Eliminating inappropriate telemetry monitoring: an evidence-based implementation guide RY Yeow, GW Strohbehn, CM Kagan, CM Petrilli, JK Krishnan, K Edholm, ... JAMA internal medicine 178 (7), 971-978, 2018 | 37 | 2018 |
| Visual arts in the clinical clerkship: a pilot cluster-randomized, controlled trial GW Strohbehn, SJK Hoffman, M Tokaz, N Houchens, R Slavin, S Winter, ... BMC medical education 20 (1), 481, 2020 | 31 | 2020 |
| De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer AK Bryant, K Sankar, L Zhao, GW Strohbehn, D Elliott, D Moghanaki, ... European Journal of Cancer 171, 55-63, 2022 | 26 | 2022 |
| Timing of adjuvant durvalumab initiation is not associated with outcomes in stage III non-small cell lung cancer AK Bryant, K Sankar, GW Strohbehn, L Zhao, D Elliott, V Daniel, ... International Journal of Radiation Oncology* Biology* Physics 113 (1), 60-65, 2022 | 24 | 2022 |
| The tyranny of non-inferiority trials IF Tannock, M Buyse, M De Backer, H Earl, DA Goldstein, MJ Ratain, ... The Lancet Oncology 25 (10), e520-e525, 2024 | 23 | 2024 |
| Adoption of extended-interval dosing of single-agent pembrolizumab and comparative effectiveness vs standard dosing in time-to-treatment discontinuation GW Strohbehn, R Holleman, J Burns, ML Klamerus, MJ Kelley, EA Kerr, ... JAMA oncology 8 (11), 1663-1667, 2022 | 20 | 2022 |
Mark RatainLeon O. Jacobson Professor of Medicine, The University of ChicagoVerified email at uchicago.edu
